Navigation Links
PharmaVentures Appoints Andy Smith as Head of Corporate Finance
Date:10/4/2011

OXFORD, England, October 4, 2011 /PRNewswire/ --

PharmaVentures today announced the appointment of Andy Smith as Head of Corporate Finance to significantly enhance Pharmaventures' advisory capabilities and offerings to the global healthcare and investment communities.

Fintan Walton, PhD, PharmaVentures' Chief Executive Office says "We are delighted to welcome Andy to PharmaVentures.  He brings a wealth of investment management experience and has also worked extensively across R&D and marketing in the healthcare sector. At PharmaVentures we are increasingly providing more investment bank style services to help our clients with their dealmaking and Andy's addition to PharmaVentures will therefore be of great benefit."

Andy has a PhD in molecular Biology and an MBA in International Marketing.  He has previously worked with Investment Managers 3i, Schroders Plc and AXA Framlington.  In 2007 he was awarded the techmark Technology Fund Manager of the year.  Since 2011 Andy has written a regular weekly column; Stockwatch, in Scrip and has lectured on healthcare valuations and modeling at the University of Cambridge for the last six years.

PharmaVentures Limited (http://www.pharmaventures.com) is a leading international corporate advisory firm supporting its clients' growth ambitions in the health care industry. It has considerable experience and expertise in the field of tangible and intangible transactions, providing advice at both a strategic level, as well as acting as advisor and broker at an implementation level. Its transactional experience includes licensing, joint ventures, mergers, acquisitions and divestments. Its clients are worldwide, including Europe, the USA and AsiaPacific. Clients range from start-ups to global pharmaceutical corporations, diversified industrial corporations, investment houses and government bodies. Its subsidiary PharmaTelevision produces the highly popular PharmaDeals® range of intelligence products including analysis tools and reports as well as the world's first dedicated online pharmaceutical television channel PharmaTelevision® (http://www.pharmatelevision.com).

Now in its 20th year, PharmaVentures is based in Oxford, UK, and employs over 30 people.


For further information
Fintan Walton, CEO
+44-1865-332733
odette.hodder@pharmaventures.com


'/>"/>
SOURCE PharmaVentures
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
2. Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU)
3. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
4. PharmaVentures Assists Helsinn in the Successful Sale of Helsinn Chemicals Ireland to the Medinco C.F.M. Group
5. Merck Engages PharmaVentures to Assist in the Divestment of its Italian Research Centre IRBM
6. Redwood Bioscience Appoints Peter Van Vlasselaer, PhD as Executive Chairman
7. PharmAthene Appoints Brian A. Markison to the Companys Board of Directors
8. PrimeraDx Appoints Albert A. Luderer to its Board of Directors
9. Neurologix Appoints Adrian Adams as Company Chairman and Chief Executive Officer
10. Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
11. 3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... 22, 2017 , ... Pharma and biotech consulting firm ... Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, Mr. Perkins brings 14 years ... than a decade with leading market research firm, GfK. He began his pharma ...
(Date:2/22/2017)... Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2017 ... ) today announced its financial results for the ... "Our annual 2016 financial results reflect continued ... earnings exceeded $700 million," said Martine Rothblatt, Ph.D., ... financial results strengthen our ability to develop and ...
(Date:2/21/2017)... , Feb. 21, 2017 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... and operational results for the three months ended December 31, ... -based life sciences and diagnostics company that develops and ... ... continue to build on the commercial milestones achieved in fiscal ...
(Date:2/21/2017)... ... February 21, 2017 , ... Vortex Biosciences announced ... automated benchtop system for collecting intact circulating tumor cells (CTCs) that are shed ... Medicine Tri Conference (Tri-Con) Annual Meeting 2017 (February 19–24 San Francisco). , The ...
Breaking Biology Technology:
(Date:2/7/2017)... 7, 2017 Ipsidy Inc. ( ... [OTC: IDGS], ("Ipsidy" or the "Company") a provider of ... services, is pleased to announce the following changes as ... Effective January 31, 2017, Philip D. Beck ... and President.  An experienced payment industry professional and public ...
(Date:2/3/2017)...  Texas Biomedical Research Institute announced that its Board of ... as the Institute,s new President and CEO. Dr. Schlesinger will ... He is currently the Chair of the Department of Microbial ... Interface Biology at Ohio State University. "We are ... CEO of Texas Biomed," said Dr. James O. Rubin ...
(Date:2/2/2017)... Fla. , Feb. 2, 2017   ... a clinical-stage immuno-oncology company specializing in the development ... for the treatment of cancer and metastatic disease, ... scale-up and GMP manufacturing of a second clinical ... vaccine targeting folate receptor alpha. The manufactured vaccine ...
Breaking Biology News(10 mins):